197 related articles for article (PubMed ID: 7760095)
1. A rat glioma model, CNS-1, with invasive characteristics similar to those of human gliomas: a comparison to 9L gliosarcoma.
Kruse CA; Molleston MC; Parks EP; Schiltz PM; Kleinschmidt-DeMasters BK; Hickey WF
J Neurooncol; 1994; 22(3):191-200. PubMed ID: 7760095
[TBL] [Abstract][Full Text] [Related]
2. Rat brain tumor models in experimental neuro-oncology: the 9L, C6, T9, F98, RG2 (D74), RT-2 and CNS-1 gliomas.
Barth RF
J Neurooncol; 1998 Jan; 36(1):91-102. PubMed ID: 9525831
[TBL] [Abstract][Full Text] [Related]
3. Invasive phenotype observed in 1,3-bis(2-chloroethyl)-1-nitrosourea-resistant sublines of 9L rat glioma cells: a tumor model mimicking a recurrent malignant glioma.
Saito R; Bringas J; Mirek H; Berger MS; Bankiewicz KS
J Neurosurg; 2004 Nov; 101(5):826-31. PubMed ID: 15540922
[TBL] [Abstract][Full Text] [Related]
4. Leptomeningeal tissue: a barrier against brain tumor cell invasion.
Pedersen PH; Rucklidge GJ; Mørk SJ; Terzis AJ; Engebraaten O; Lund-Johansen M; Backlund EO; Laerum OD; Bjerkvig R
J Natl Cancer Inst; 1994 Nov; 86(21):1593-9. PubMed ID: 7932823
[TBL] [Abstract][Full Text] [Related]
5. Human and rat glioma growth, invasion, and vascularization in a novel chick embryo brain tumor model.
Cretu A; Fotos JS; Little BW; Galileo DS
Clin Exp Metastasis; 2005; 22(3):225-36. PubMed ID: 16158250
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the 9L gliosarcoma implanted in the Fischer rat: an orthotopic model for a grade IV brain tumor.
Bouchet A; Bidart M; Miladi I; Le Clec'h C; Serduc R; Coutton C; Regnard P; Khalil E; Dufort S; Lemasson B; Laissue J; Pelletier L; Le Duc G
Tumour Biol; 2014 Jul; 35(7):6221-33. PubMed ID: 24633919
[TBL] [Abstract][Full Text] [Related]
7. Honokiol crosses BBB and BCSFB, and inhibits brain tumor growth in rat 9L intracerebral gliosarcoma model and human U251 xenograft glioma model.
Wang X; Duan X; Yang G; Zhang X; Deng L; Zheng H; Deng C; Wen J; Wang N; Peng C; Zhao X; Wei Y; Chen L
PLoS One; 2011 Apr; 6(4):e18490. PubMed ID: 21559510
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of a transmembrane isoform of neural cell adhesion molecule alters the invasiveness of rat CNS-1 glioma.
Owens GC; Orr EA; DeMasters BK; Muschel RJ; Berens ME; Kruse CA
Cancer Res; 1998 May; 58(9):2020-8. PubMed ID: 9581848
[TBL] [Abstract][Full Text] [Related]
9. Characterization of gastrin-induced cytostatic effect on cell proliferation in experimental malignant gliomas.
Lefranc F; Sadeghi N; Metens T; Brotchi J; Salmon I; Kiss R
Neurosurgery; 2003 Apr; 52(4):881-90; discussion 890-1. PubMed ID: 12657185
[TBL] [Abstract][Full Text] [Related]
10. Immunization with an antigen identified by cytokine tumor vaccine-assisted SEREX (CAS) suppressed growth of the rat 9L glioma in vivo.
Okada H; Attanucci J; Giezeman-Smits KM; Brissette-Storkus C; Fellows WK; Gambotto A; Pollack LF; Pogue-Geile K; Lotze MT; Bozik ME; Chambers WH
Cancer Res; 2001 Mar; 61(6):2625-31. PubMed ID: 11289140
[TBL] [Abstract][Full Text] [Related]
11. Glial cell line-derived neurotrophic factor (GDNF) and its receptor (GFR-alpha 1) are strongly expressed in human gliomas.
Wiesenhofer B; Stockhammer G; Kostron H; Maier H; Hinterhuber H; Humpel C
Acta Neuropathol; 2000 Feb; 99(2):131-7. PubMed ID: 10672319
[TBL] [Abstract][Full Text] [Related]
12. Establishment of a new cell line derived from a human gliosarcoma.
Iwasaki K; Kikuchi H; Miyatake S; Kondo S; Oda Y
Neurosurgery; 1992 Feb; 30(2):228-35. PubMed ID: 1545891
[TBL] [Abstract][Full Text] [Related]
13. Microglia phagocytose alloreactive CTL-damaged 9L gliosarcoma cells.
Kulprathipanja NV; Kruse CA
J Neuroimmunol; 2004 Aug; 153(1-2):76-82. PubMed ID: 15265665
[TBL] [Abstract][Full Text] [Related]
14. Rat brain tumor models in experimental neuro-oncology: the C6, 9L, T9, RG2, F98, BT4C, RT-2 and CNS-1 gliomas.
Barth RF; Kaur B
J Neurooncol; 2009 Sep; 94(3):299-312. PubMed ID: 19381449
[TBL] [Abstract][Full Text] [Related]
15. 7-Hydroxystaurosporine-induced apoptosis in 9L glioma cells provides an effective antigen source for dendritic cells and yields a potent vaccine strategy in an intracranial glioma model.
Witham TF; Erff ML; Okada H; Chambers WH; Pollack IF
Neurosurgery; 2002 Jun; 50(6):1327-34; discussion 1334-5. PubMed ID: 12015852
[TBL] [Abstract][Full Text] [Related]
16. Cytokine gene therapy of gliomas: induction of reactive CD4+ T cells by interleukin-4-transfected 9L gliosarcoma is essential for protective immunity.
Giezeman-Smits KM; Okada H; Brissette-Storkus CS; Villa LA; Attanucci J; Lotze MT; Pollack IF; Bozik ME; Chambers WH
Cancer Res; 2000 May; 60(9):2449-57. PubMed ID: 10811123
[TBL] [Abstract][Full Text] [Related]
17. Expression of a soluble transforming growth factor-beta (TGFbeta) receptor reduces tumorigenicity by regulating natural killer (NK) cell activity against 9L gliosarcoma in vivo.
Witham TF; Villa L; Yang T; Pollack IF; Okada H; Robbins PD; Chambers WH
J Neurooncol; 2003; 64(1-2):63-9. PubMed ID: 12952287
[TBL] [Abstract][Full Text] [Related]
18. Paracrine delivery of IL-12 against intracranial 9L gliosarcoma in rats.
DiMeco F; Rhines LD; Hanes J; Tyler BM; Brat D; Torchiana E; Guarnieri M; Colombo MP; Pardoll DM; Finocchiaro G; Brem H; Olivi A
J Neurosurg; 2000 Mar; 92(3):419-27. PubMed ID: 10701528
[TBL] [Abstract][Full Text] [Related]
19. Development of experimental models for meningeal neoplasia using intrathecal injection of 9L gliosarcoma and Walker 256 carcinosarcoma in the rat.
Kooistra KL; Rodriguez M; Powis G; Yaksh TL; Harty GJ; Hilton JF; Laws ER
Cancer Res; 1986 Jan; 46(1):317-23. PubMed ID: 3753551
[TBL] [Abstract][Full Text] [Related]
20. Intracranial inhibition of glioma cell growth by cyclooxygenase-2 inhibitor celecoxib.
Nam DH; Park K; Park C; Im YH; Kim MH; Lee S; Hong SC; Shin HJ; Kim JH; Eoh W; McDonnell TJ
Oncol Rep; 2004 Feb; 11(2):263-8. PubMed ID: 14719052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
